Cargando…

Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)

(1) Background: new generations of rFVIII products offered the possibility to improve personalized therapeutic approaches, reducing the number of infusions or increasing the protection against bleeding risk. The aim of this study was to assess the effectiveness of prophylaxis with BAY 81-8973 (octoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortesi, Paolo Angelo, Di Minno, Giovanni, Zanon, Ezio, Giuffrida, Gaetano, Santoro, Rita Carlotta, Marino, Renato, D’Angiolella, Lucia Sara, Antonazzo, Ippazio Cosimo, Squassabia, Ginevra, Clemente, Francesco, Di Laura, Danilo, Cimino, Ernesto, Pasca, Samantha, Nicolosi, Daniela, Mantovani, Lorenzo Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224869/ https://www.ncbi.nlm.nih.gov/pubmed/35743504 http://dx.doi.org/10.3390/jcm11123434

Ejemplares similares

Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81–8973): Final results of the global real‐world study, TAURUS
por: Santoro, Cristina, et al.
Publicado: (2022)

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials
por: Kenet, Gili, et al.
Publicado: (2023)

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
por: Santoro, Cristina, et al.
Publicado: (2020)

Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial
por: Yang, Renchi, et al.
Publicado: (2019)

Efficiency measures of emergency departments: an Italian systematic literature review
por: Di Laura, Danilo, et al.
Publicado: (2021)

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
por: Mahlangu, Johnny, et al.
Publicado: (2020)

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
por: Pocoski, Jennifer, et al.
Publicado: (2016)

Acquired Haemophilia A in the Elderly: Case Reports
por: Tufano, Antonella, et al.
Publicado: (2010)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

Octocog alfa: Lack of efficacy: case report
Publicado: (2022)

Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
por: Kavakli, K, et al.
Publicado: (2015)

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
por: Reding, Mark T., et al.
Publicado: (2023)

Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis
por: O’Hara, Jamie, et al.
Publicado: (2021)

BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial
por: Ljung, Rolf, et al.
Publicado: (2023)

Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Consensus statements on vaccination in patients with haemophilia—Results from the Italian haemophilia and vaccinations (HEVA) project
por: Santagostino, Elena, et al.
Publicado: (2019)

Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians
por: Borchiellini, Alessandra, et al.
Publicado: (2021)

The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2023)

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023)

Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of Haemophilia Centres
por: Di Minno, Matteo Nicola Dario, et al.
Publicado: (2021)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia
por: van Moort, Iris, et al.
Publicado: (2021)

Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81–8973 compared with other full-length rFVIII products
por: Teare, John M, et al.
Publicado: (2019)

Rehabilitation management of a triceps surae muscle injury in a young male with haemophilia A and high-titre inhibitors
por: Frizziero, Antonio, et al.
Publicado: (2021)

A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy
por: Zambelli, Alberto, et al.
Publicado: (2023)

Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia
por: Turecek, Peter L., et al.
Publicado: (2020)

Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A
por: Shah, Anita, et al.
Publicado: (2016)

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
por: Solms, Alexander, et al.
Publicado: (2020)

A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2023)

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A
por: Di Minno, Giovanni, et al.
Publicado: (2019)

Efficacy of Octocog Alfa (Advate) in a Child with Type 3 von Willebrand Disease and Alloantibodies
por: Sottilotta, Gianluca, et al.
Publicado: (2017)

Identification of a novel mutation in the factor VIII gene causing severe haemophilia A
por: Nissen, S. K., et al.
Publicado: (2018)

Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A
por: Persson, Sofie, et al.
Publicado: (2022)

Ex vivo factor VIII‐modified proliferating human hepatocytes therapy for haemophilia A
por: Zhang, Kun, et al.
Publicado: (2023)

How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report
por: Zanon, Ezio, et al.
Publicado: (2020)

It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer
por: Carlucci, A, et al.
Publicado: (2015)

Keeping CDK18 in balance to prevent DNA replication stress in breast cancer
por: Braams, Esmée, et al.
Publicado: (2018)

Two paths to let the replisome go
por: D'Angiolella, Vincenzo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4vi7tsp5bdq2j31arkg3lnpb90